Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vaccines targeting p53 mutants elicit anti-tumor immunity.

Cancer letters - 28 Feb 2025

Chai Dafei, Wang Xu, Fan Chunmei, Wang Junhao, Lim Jing Ming, Yu Xinfang, Young Ken H, Li Yong

Abstract excerpt

The p53 tumor suppressor is commonly mutated in cancer; however, there are no effective treatments targeting p53 mutants. A DNA vaccine gWIZ-S237G targeting the p53 S237G mutant, which is highly expressed in A20 murine tumor cells, was developed and administered intramuscularly via electroporation, either alone or in combination with PD-1 blockade. The anti-p53-S237G immunization elicited a robust protective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Vaccines
Share to CD8-Positive T-Lymphocytes
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liver Neoplasms

Share to Mice, Inbred C57BL

Share to Programmed Cell Death 1 Receptor

Share to Tumor Suppressor Protein p53

Share to Vaccines, DNA

Source

Open in PubMed Open full text

Identifiers

PMID: 39740750
DOI: 10.1016/j.canlet.2024.217421
PMCID: PMC12924686

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vaccines targeting p53 mutants elicit anti-tumor immunity.PMID 39740750Read ↗

Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant.Semantic proximity Read ↗

Anticancer therapeutic strategies for targeting mutant p53-Y220CSemantic proximity Read ↗

p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses.Semantic proximity Read ↗

A p53 peptide mucosal vaccine induces cellular and humoral immunity and anti-tumor effects in a murine colorectal cancer modelSemantic proximity Read ↗

Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responsesSemantic proximity Read ↗

TP53 Mutation-Mediated Immune Evasion in Cancer: Mechanisms and Therapeutic ImplicationsSemantic proximity Read ↗

New perspective on targeting the tumor suppressor p53 pathway in the tumor microenvironment to enhance the efficacy of immunotherapySemantic proximity Read ↗

The Role of p53 in Nanoparticle-Based Therapy for CancerSemantic proximity Read ↗

p53 mutation and deletion contribute to tumor immune evasionSemantic proximity Read ↗

Regulation of cytotoxic T-cell responses by p53 in cancerSemantic proximity Read ↗

DNA-delivered monoclonal antibodies targeting the p53 R175H mutant epitope inhibit tumor development in miceSemantic proximity Read ↗

Revisiting tumor immunogenicity through the lens of mutant p53: Implications for cancer immunotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.